eXoZymes Stock News

Program expected to commence in Q4 2026 and establish a roadmap for larger-scale production in 2027 LOS ANGELES, CA / ACCESS Newswire / September 8, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced that it has entered into an agreement with Curia Global, Inc. (...

Management to host Q2 2026 update at 5PM ET / 2PM PT, today. LOS ANGELES, CA / ACCESS Newswire / August 20, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - will host an investor webinar today at 5:00 PM Eastern Time to discuss results for the second quarter ended June 3...

Optimized process delivered a 10-fold improvement in productivity, significantly improving the estimated economics of future commercial-scale manufacturing. Estimated manufacturing cost equivalent has fallen more than 100x from the first version of the NCT process to the current optimized process, based on internal process-cost assessments.

Company to collaborate with Lawrence Berkeley National Laboratory on AI-enabled digital twins designed to accelerate optimization of enzyme-driven manufacturing processes. The 9-month project awarded approximately $747,000 in total funding, including $147,000 awarded to eXoZymes Expands eXoZymes' AI strategy beyond enzyme engineering into AI-guided manufacturing, leveraging digital twins to pre...

Award allows eXoZymes to expand its portfolio of proprietary new-to-nature molecules and potential future pharmaceutical assets and validates the Company's ability to make rare cannabinoids and new cannabinoid-like molecules. NIH-backed work on the two-year grant is expected to begin on July 1, 2026, and represents the second biosolution in eXoZymes' pipeline after NCT advancing towards partner...